FOCINVEZ

Growth

fosaprepitant dimeglumine

NDAINTRAVENOUSSOLUTION

Approved

Aug 2023

Lifecycle

Growth

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing…

Indications (7)

older for the prevention of: acute delayed nausea vomiting associated with initial repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin older combination with other antiemetic agents for the prevention of : acute

Clinical Trials (3)

NCT03578081Phase 3Completed

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Started Nov 2018

690 enrolled

Malignant Neoplasm

NCT01594749Phase 3Completed

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Started Sep 2012

1,015 enrolled

Chemotherapy-Induced Nausea and Vomiting (CINV)

NCT01031953Phase 1/2Terminated

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

Started Aug 2008

34 enrolled